The effects of moclobemide, a new selective and reversible MAO-A inhibitor, on cognitive function and psychomotor performance were measured in 12 healthy elderly male volunteers (with a mean age of 72.5 years). Subjects received moclobemide 200 mg, amitriptyline (positive internal control) 25 mg or
The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers
โ Scribed by D. B. Fairweather; J. S. Kerr; I. Hindmarch
- Publisher
- Springer
- Year
- 1992
- Tongue
- English
- Weight
- 749 KB
- Volume
- 43
- Category
- Article
- ISSN
- 0031-6970
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
The daytime psychomotor performance of 12 healthy subjects of mean age 81.4 years was examined in a double-blind crossover study following single and repeated nightly doses of nitrazepam 5 mg, lormetazepam 1 mg, and placebo. Accuracy of performance on the Gibson spiral maze was unaffected by both dr
The effects of a 10 day administration of clomipramine (25-50 mg t.i.d.), alprazolam (0.25-0.75 mg t.i.d.) and placebo were assessed in normal volunteers in a double-blind cross-over study. A battery of physiological, psychomotor and cognitive tests was administered both before and 3 h after drug on
This was a randomized double blind, placebo-controlled cross over study performed on 12 healthy female volunteers. It consisted of three treatment sessions of 7 days separated by a one week wash out period. The objectives of the study were to assess the sedative activity of 2 muscle relaxant drugs:
## Abstract Brofaromine is a novel antidepressant that functions by the inhibition of the A form of monoamine oxidase (MAO). This inhibition is reversible, making brofaromine both pharmacologically and structurally different from most of the currently available MAO inhibitors. The drug has been sho
This study investigated the effects of acute doses of Ginkgo biloba extract (GBE) on memory and psychomotor performance in a randomized, double-blind and placebo controlled 5-way cross-over design. Thirty-one volunteers aged 30-59 years received GBE 150 mg (50 mg t.d.s), GBE 300 mg (100 mg t.d.s.),